Platt Heather L.
Podsumowanie dorobku w bazie danych
2
publikacji (2019–2026)
11,861
łączny Impact Factor
300
łącznie punktów MNiSW
Identyfikatory
PBN
Profil w PBN BPP ID
43380Publikacje w latach
10
Punkty MNiSW w latach
200,000
Impact Factor w latach
8,3000
Statystyki wg charakteru
| Charakter formalny | Liczba prac |
|---|---|
| 2 |
Wyszukaj publikacje autora
Bez zaznaczonych filtrów wyszukiwanie pokaże wszystkie prace autora. Zaznacz typy, lata lub jednostki, żeby zawęzić wyniki.
Eksport publikacji
Najlepsze prace (punkty MNiSW)
- A phase 3, randomized trial investigating the safety, tolerability, and immunogenicity of V116, an adult-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve ndults 18-64 years of age at increased risk of pneumococcal disease, STRIDE-8. [AUT. KORESP.] PAUL T. SCOTT, [AUT.] JAYANI PATHIRANA, AKIRA KATO, RICHARD TYTUS, CARLOS M. PEREZ, NIGEL LESLIE GILCHRIST, HIDEMI KANOU, KWANG HA YOO, GRZEGORZ KANIA, MICHAEL NISSEN, AMY FALK RUSSELL, DOREEN FERNSLER, MUHAMMAD WALEED, JIANING LI, ULRIKE K. BUCHWALD, HEATHER L. PLATT, the STRIDE-8 Study Group. Clin. Infect. Dis. 2026 vol. 82 nr 2 s. e217-e226, bibliogr. poz. 39. DOI: 10.1093/cid/ciaf604
- Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. [AUT. KORESP.] ERIC LAWITZ, [AUT.] EDWARD GANE, JORDAN J. FELD, MARIA BUTI, GRAHAM R. FOSTER, MORDECHAI RABINOVITZ, EDUARD BURNEVICH, HELENA KATCHMAN, KRZYSZTOF TOMASIEWICZ, FRED LAHSER, BETH JACKSON, MELISSA SHAUGHNESSY, STEPHANIE KLOPFER, WENDY W. YEH, MICHAEL N. ROBERTSON, GEORGE J. HANNA, ELIAV BARR, HEATHER L. PLATT, ON BEHALF OF THE C‐BREEZE‐2 STUDY INVESTIGATORS. J. Viral Hepat. 2019 vol. 26 nr 9 s. 1127-1138, bibliogr. DOI: 10.1111/jvh.13132
Najlepsze prace (Impact Factor)
- A phase 3, randomized trial investigating the safety, tolerability, and immunogenicity of V116, an adult-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve ndults 18-64 years of age at increased risk of pneumococcal disease, STRIDE-8. [AUT. KORESP.] PAUL T. SCOTT, [AUT.] JAYANI PATHIRANA, AKIRA KATO, RICHARD TYTUS, CARLOS M. PEREZ, NIGEL LESLIE GILCHRIST, HIDEMI KANOU, KWANG HA YOO, GRZEGORZ KANIA, MICHAEL NISSEN, AMY FALK RUSSELL, DOREEN FERNSLER, MUHAMMAD WALEED, JIANING LI, ULRIKE K. BUCHWALD, HEATHER L. PLATT, the STRIDE-8 Study Group. Clin. Infect. Dis. 2026 vol. 82 nr 2 s. e217-e226, bibliogr. poz. 39. DOI: 10.1093/cid/ciaf604
- Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. [AUT. KORESP.] ERIC LAWITZ, [AUT.] EDWARD GANE, JORDAN J. FELD, MARIA BUTI, GRAHAM R. FOSTER, MORDECHAI RABINOVITZ, EDUARD BURNEVICH, HELENA KATCHMAN, KRZYSZTOF TOMASIEWICZ, FRED LAHSER, BETH JACKSON, MELISSA SHAUGHNESSY, STEPHANIE KLOPFER, WENDY W. YEH, MICHAEL N. ROBERTSON, GEORGE J. HANNA, ELIAV BARR, HEATHER L. PLATT, ON BEHALF OF THE C‐BREEZE‐2 STUDY INVESTIGATORS. J. Viral Hepat. 2019 vol. 26 nr 9 s. 1127-1138, bibliogr. DOI: 10.1111/jvh.13132
Najnowsze artykuły
- A phase 3, randomized trial investigating the safety, tolerability, and immunogenicity of V116, an adult-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve ndults 18-64 years of age at increased risk of pneumococcal disease, STRIDE-8. [AUT. KORESP.] PAUL T. SCOTT, [AUT.] JAYANI PATHIRANA, AKIRA KATO, RICHARD TYTUS, CARLOS M. PEREZ, NIGEL LESLIE GILCHRIST, HIDEMI KANOU, KWANG HA YOO, GRZEGORZ KANIA, MICHAEL NISSEN, AMY FALK RUSSELL, DOREEN FERNSLER, MUHAMMAD WALEED, JIANING LI, ULRIKE K. BUCHWALD, HEATHER L. PLATT, the STRIDE-8 Study Group. Clin. Infect. Dis. 2026 vol. 82 nr 2 s. e217-e226, bibliogr. poz. 39. DOI: 10.1093/cid/ciaf604
- Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. [AUT. KORESP.] ERIC LAWITZ, [AUT.] EDWARD GANE, JORDAN J. FELD, MARIA BUTI, GRAHAM R. FOSTER, MORDECHAI RABINOVITZ, EDUARD BURNEVICH, HELENA KATCHMAN, KRZYSZTOF TOMASIEWICZ, FRED LAHSER, BETH JACKSON, MELISSA SHAUGHNESSY, STEPHANIE KLOPFER, WENDY W. YEH, MICHAEL N. ROBERTSON, GEORGE J. HANNA, ELIAV BARR, HEATHER L. PLATT, ON BEHALF OF THE C‐BREEZE‐2 STUDY INVESTIGATORS. J. Viral Hepat. 2019 vol. 26 nr 9 s. 1127-1138, bibliogr. DOI: 10.1111/jvh.13132
Ostatnio edytowane
- A phase 3, randomized trial investigating the safety, tolerability, and immunogenicity of V116, an adult-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve ndults 18-64 years of age at increased risk of pneumococcal disease, STRIDE-8. [AUT. KORESP.] PAUL T. SCOTT, [AUT.] JAYANI PATHIRANA, AKIRA KATO, RICHARD TYTUS, CARLOS M. PEREZ, NIGEL LESLIE GILCHRIST, HIDEMI KANOU, KWANG HA YOO, GRZEGORZ KANIA, MICHAEL NISSEN, AMY FALK RUSSELL, DOREEN FERNSLER, MUHAMMAD WALEED, JIANING LI, ULRIKE K. BUCHWALD, HEATHER L. PLATT, the STRIDE-8 Study Group. Clin. Infect. Dis. 2026 vol. 82 nr 2 s. e217-e226, bibliogr. poz. 39. DOI: 10.1093/cid/ciaf604
- Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. [AUT. KORESP.] ERIC LAWITZ, [AUT.] EDWARD GANE, JORDAN J. FELD, MARIA BUTI, GRAHAM R. FOSTER, MORDECHAI RABINOVITZ, EDUARD BURNEVICH, HELENA KATCHMAN, KRZYSZTOF TOMASIEWICZ, FRED LAHSER, BETH JACKSON, MELISSA SHAUGHNESSY, STEPHANIE KLOPFER, WENDY W. YEH, MICHAEL N. ROBERTSON, GEORGE J. HANNA, ELIAV BARR, HEATHER L. PLATT, ON BEHALF OF THE C‐BREEZE‐2 STUDY INVESTIGATORS. J. Viral Hepat. 2019 vol. 26 nr 9 s. 1127-1138, bibliogr. DOI: 10.1111/jvh.13132
Osadź publikacje tego autora na swojej stronie WWW — kliknij tutaj.